Appointments

Move of the month

Prilenia, a clinical stage biotech focusing on neurodegenerative and neurodevelopmental disorders, has announced the appointment of two new senior staff members ‒ Rob Lauzen as chief financial officer (CFO) and Jason Marks as chief legal officer (CLO).

Rob Lauzen, most recently vice president of Investor Relations and head of Financial Planning & Analysis at Dyne Therapeutics, has nearly a decade of strategic and financial experience. In the past, he served as a vice president at Morgan Stanley. At Prilenia, Rob will oversee the company’s capital strategy and finance and investor relations organisations.

Jason Marks has over 20 years of counsel experience, most recently at Teva, and has served as CLO, chief commercial officer and corporate secretary for various companies. He has also held senior positions at Bausch Health, Alcon and Stryker where he had a broad array of legal, operational, governance and compliance responsibilities.

Jason will have a key strategic role at Prilenia, and oversee the legal and compliance functions.

Dr Michael R Hayden, CEO of Prilenia, commented: “This is a transformational time for Prilenia. Rob and Jason bring outstanding expertise to the company. More than that, they join our efforts to take pridopidine to patients, bringing broad and deep knowledge of what it takes to deliver success. I have no doubt that Rob and Jason will make important contributions as we strive to achieve our goals.”